Tigermed-Jyton Announces Acquisition of NAMSA China and Global Strategic Partnership with NAMSA
- 2024-02-29
- By Tigermed-Jyton
BEIJING, CHINA and TOLEDO, US –February 29, 2024—Tigermed-Jyton, a leading medical device CRO in China, and NAMSA, a global leader MedTech Contract Research Organization (CRO) offering global end-to-end development services, today announced Tigermed-Jyton’s acquisition of NAMSA China, as well as the exclusive China regional partnership and global collaboration between Tigermed-Jyton and NAMSA.
Tigermed-Jyton is a leading medical device CRO in China offering full life cycle services and global expertise in all stages of the medical device development process. The company offers services including R&D Strategy, Medical Device Testing, Quality Systems, Clinical Evaluation Reports, Clinical Trials, Regulatory Affairs, and other consulting services. As a subsidiary of Tigermed Group, Tigermed-Jyton’s service capability covers more than 50 countries and regions across Asia Pacific, North America, and the European Union.
NAMSA, China, as one of NAMSA’s most important regional business branches, provides end-to-end development services for companies developing medical devices, including Medical Device Consulting, Regulatory and Quality Consulting, Clinical Research, and more. The NAMSA China team has expertise in various therapeutic areas such as cardiovascular, dental, orthopedics, and ophthalmology.
“Tigermed-Jyton is excited to have NAMSA China joining our team,” said Yifei Peng, General Manager of Tigermed-Jyton. “As a leading medical device CRO in China, we hope this acquisition will synergize the resources of both parties. By partnering with NAMSA and leveraging their global brand influence, we are able to further strengthen our global service capabilities, broaden our patient-centered approach, and continue to contribute to the advancement for medical device global development.”
“NAMSA is excited about the opportunity to collaborate with Tigermed-Jyton, which is an exclusive partnership giving NAMSA’s clients the full scale of CRO services in China for the commercialization of their novel devices,” commented Dr. Christophe Berthoux, NAMSA CEO. “We recognize the current constraints that global device developers experience when it comes to finding trusted partners in China to accelerate their commercialization. By partnering with Tigermed-Jyton, we can streamline these processes, helping MedTech sponsors bring life-saving devices to market faster in China,” Berthoux concluded.
The acquisition of NAMSA China will further strengthen Tigermed-Jyton’s service capabilities and scale in China and provide better customized product R&D solutions. Leveraging Tigermed-Jyton’s rich product experience and local knowledge and expertise, this strategic partnership will more efficiently accelerate the time-to-market for NAMSA’s clients aiming to expand into the Chinese market. At the same time, with NAMSA’s global brand influence, this strategic partnership can further expand Tigermed-Jyton's global brand influence, enhance its global medical device R&D service capabilities, and assist more worldwide customers’ global expansions.
Tigermed-Jyton is a leading medical device CRO in China offering full life cycle services and global expertise in all stages of the medical device development process. The company offers services including R&D Strategy, Medical Device Testing, Quality Systems, Clinical Evaluation Reports, Clinical Trials, Regulatory Affairs, and other consulting services. As a subsidiary of Tigermed Group, Tigermed-Jyton’s service capability covers more than 50 countries and regions across Asia Pacific, North America, and the European Union.
NAMSA, China, as one of NAMSA’s most important regional business branches, provides end-to-end development services for companies developing medical devices, including Medical Device Consulting, Regulatory and Quality Consulting, Clinical Research, and more. The NAMSA China team has expertise in various therapeutic areas such as cardiovascular, dental, orthopedics, and ophthalmology.
“Tigermed-Jyton is excited to have NAMSA China joining our team,” said Yifei Peng, General Manager of Tigermed-Jyton. “As a leading medical device CRO in China, we hope this acquisition will synergize the resources of both parties. By partnering with NAMSA and leveraging their global brand influence, we are able to further strengthen our global service capabilities, broaden our patient-centered approach, and continue to contribute to the advancement for medical device global development.”
“NAMSA is excited about the opportunity to collaborate with Tigermed-Jyton, which is an exclusive partnership giving NAMSA’s clients the full scale of CRO services in China for the commercialization of their novel devices,” commented Dr. Christophe Berthoux, NAMSA CEO. “We recognize the current constraints that global device developers experience when it comes to finding trusted partners in China to accelerate their commercialization. By partnering with Tigermed-Jyton, we can streamline these processes, helping MedTech sponsors bring life-saving devices to market faster in China,” Berthoux concluded.
The acquisition of NAMSA China will further strengthen Tigermed-Jyton’s service capabilities and scale in China and provide better customized product R&D solutions. Leveraging Tigermed-Jyton’s rich product experience and local knowledge and expertise, this strategic partnership will more efficiently accelerate the time-to-market for NAMSA’s clients aiming to expand into the Chinese market. At the same time, with NAMSA’s global brand influence, this strategic partnership can further expand Tigermed-Jyton's global brand influence, enhance its global medical device R&D service capabilities, and assist more worldwide customers’ global expansions.